Subendocardial quantification enhances coronary artery disease detection in ¹⁸F-flurpiridaz PET.

ABSTRACT:

Purpose

The new high resolution positron emission tomography (PET) myocardial perfusion imaging tracer, ¹⁸F-flurpiridaz, is set to enter clinical use soon following its recent regulatory approval. We developed an approach for evaluating subendocardial analysis for stress total perfusion deficit (TPD) and ischemic TPD, assessed its performance for detection of coronary artery disease (CAD) and compared these measures to transmural analysis and expert physician assessments.

Methods

Myocardial perfusion image data from the ¹⁸F-flurpiridaz phase III clinical trial (NCT01347710) were used. The subendocardial layer was automatically defined on the left ventricular contours and used for the derivation of polar maps. Areas under the receiver operating character

SUBMITTER: Builoff V 

PROVIDER: S-EPMC12221820 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature